ABSTRACT
While the use of 18F-fluorodeoxyglucose (FDG)-PET in oncology has generated intense interest, conventional gamma-emitting radionuclides remain important and are possibly a cost-effective alternative in molecular imaging techniques for clinic use. New advances in chelate chemistry include the development of ‘‘plug and play’’ platform technology in which the imaging beacon and chelate remain the same, while a host of small molecule ligands can be substituted as needed. Combining this chemistry with automated synthesis devices creates the opportunity to generate, perhaps, hundreds of radioligands for imaging, allowing customization of patient workup in the future.
